Novartis’s Ultibro Breezhaler can reduce lung hyperinflation and improve cardiac function
February 22, 2018Novartis has announced the publication of the CLAIM study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro Breezhaler (indacaterol/glycopyrronium 110/50 mcg) significantly improved lung and cardiac function, when compared to placebo, in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation.
Many people living with COPD are at increased risk of death and disability due to comorbid cardiovascular disease. Lung hyperinflation is common in people with COPD, and has been linked to impaired cardiac function and a worsening of COPD symptoms, especially breathlessness. CLAIM is the first study to investigate the effects of dual bronchodilation on cardiac function and lung hyperinflation.
The CLAIM study met its primary endpoint demonstrating that treatment with Ultibro Breezhaler led to decreased lung hyperinflation and improvements in cardiac function after 14 days of treatment. This translated into clinically relevant patient benefits of improved health status and breathlessness (dyspnea), studied as exploratory endpoints.
Shreeram Aradhye, Chief Medical Officer and Global Head of Medical Affairs for Novartis Pharmaceuticals. “The publication of the CLAIM study is important for any COPD patient with signs of lung hyperinflation. For the first time, we demonstrated that treatment with Ultibro Breezhaler can reduce lung hyperinflation and improve cardiac function, breathlessness and health status.”
